Free tool
FAERS Monitor: Definity
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021064 or its brand name (Definity, Perflutren). Reports on generic versions are filed under their own applications.
Reports
5,709
Serious
1,899
33% of reports
Hospitalization
401
Death reported
116
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- back pain2,424
- dyspnoea800
- muscle spasms755
- pain in extremity504
- flushing414
- chest pain403
- headache382
- dizziness331
- urticaria305
- neck pain304
- nausea274
- arthralgia244
- pruritus215
- erythema213
- anaphylactic reaction205
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 135 |
| 2005 | 195 |
| 2006 | 342 |
| 2007 | 628 |
| 2008 | 279 |
| 2009 | 35 |
| 2010 | 31 |
| 2011 | 15 |
| 2012 | 23 |
| 2013 | 29 |
| 2014 | 20 |
| 2015 | 64 |
| 2016 | 244 |
| 2017 | 222 |
| 2018 | 187 |
| 2019 | 209 |
| 2020 | 252 |
| 2021 | 251 |
| 2022 | 501 |
| 2023 | 528 |
| 2024 | 509 |
| 2025 | 612 |
| 2026 | 398 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,450 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| back painSignal | 2,424 | 38.8 | 37.7 | 89,368 |
| neck painSignal | 304 | 20.1 | 18.1 | 5,497 |
| muscle spasmsSignal | 755 | 15.2 | 14.2 | 10,059 |
| flushingSignal | 414 | 15.1 | 13.7 | 5,425 |
| anaphylactic reactionSignal | 205 | 13.7 | 12.0 | 2,401 |
| chest painSignal | 403 | 8.0 | 7.3 | 2,490 |
| urticariaSignal | 305 | 6.7 | 6.0 | 1,488 |
| pain in extremitySignal | 504 | 6.3 | 5.8 | 2,275 |
| dyspnoeaSignal | 800 | 5.2 | 4.9 | 2,790 |
| erythemaSignal | 213 | 3.8 | 3.3 | 445 |
| dizzinessSignal | 331 | 2.4 | 2.2 | 288 |
| headacheSignal | 382 | 2.2 | 2.0 | 271 |
| arthralgiaSignal | 244 | 2.2 | 1.9 | 154 |
| pruritusSignal | 215 | 2.1 | 1.8 | 119 |
| nausea | 274 | 1.3 | 1.1 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.